Recently, American Heart Association (AHA) recommended sodium-glucose cotransporter 2 (SGLT2) inhibitors as first-line therapy for patients with heart failure, independently of the presence of type 2 diabetes [65]. Here, SLC5A2 is linked to heart failure.